Abstract

RemeGen Co., Ltd. will release its quarterly results on August 24, 2026 post-Market; based on interim guidance and Q1 disclosures, investors anticipate a licensing-driven step-up in revenue and profit, with attention on the sustainability of product sales momentum alongside the one-off uplift from collaboration income.

Market Forecast

Consensus expectations center on a sharp quarter-on-quarter surge as collaboration income is recognized: using the company’s half-year preannouncement of approximately 5.85 billion RMB in operating revenue and about 4.70 billion RMB in net profit for the first half, the market implies second-quarter revenue around 5.19 billion RMB and net profit around 4.37 billion RMB, while adjusted EPS and detailed margin guidance for the quarter have not been disclosed. The revenue mix is expected to skew to high-margin technology licensing and collaboration income this quarter, likely lifting overall profitability above the level achieved in the first quarter; adjusted EPS guidance is not available, and year-over-year metrics for the quarter are not disclosed, though the company indicated a 433% year-over-year increase for first-half revenue.

The main commercial operations are expected to continue expanding on the back of telitacicept and disitamab vedotin sales, with the new indication approval for telitacicept in Sjögren’s syndrome during the quarter adding support to demand. The most promising near-term revenue driver is the RC148 out-licensing arrangement, which, together with product sales, underpins the implied 5.19 billion RMB revenue for the quarter and contributed to the 433% year-over-year uplift in first-half operating revenue.

Last Quarter Review

In the previous quarter, RemeGen Co., Ltd. generated 656.21 million RMB in revenue, posted a gross profit margin of 82.18%, delivered 328.00 million RMB in net profit attributable to the parent, achieved a net profit margin of 49.98%, and did not disclose adjusted EPS or year-over-year comparisons. The profitability profile reflected a high-value product mix and disciplined operating execution during a period preceding major collaboration income recognition. By segment presentation, Biopharmaceutical Research, Service, Production and Sales recorded 656.21 million RMB in revenue; year-over-year segment growth was not disclosed, though management commentary and subsequent announcements pointed to momentum in telitacicept and disitamab vedotin.

Current Quarter Outlook

Main commercial operations

RemeGen Co., Ltd.’s domestic commercialization remains the core of its recurring revenue base this quarter. The product portfolio led by telitacicept and disitamab vedotin is positioned to build on first-quarter performance, and the second-quarter approval of a new indication for telitacicept in Sjögren’s syndrome offers an incremental demand catalyst embedded within the quarter’s run-rate sales. While the quarter-on-quarter step-up will be dominated by collaboration income, the product revenue trajectory remains important for gauging the health of the underlying business, particularly as the company moves beyond the near-term licensing uplift.

Margin dynamics within this business are expected to remain favorable relative to typical industry averages due to the contribution from higher-value biologics; however, the blended margin for the quarter will be driven primarily by the mix effect from collaboration income. Inventory and channel conditions will likely remain orderly, as there has been no signal of material product rebate or pricing changes in the period under review. Looking to the next two quarters, ongoing label and indication expansion, together with broader academic exposure achieved through major medical congress data presentations, should support the visibility of hospital formulary uptake and physician adoption.

The key qualitative indicator to track within the quarter is the balance between recurring product revenue growth and collaboration income recognition. If the quarterly disclosure delineates these lines clearly, investors will be able to extrapolate a more stable revenue trajectory for the ensuing quarters, which can influence how the market capitalizes near-term earnings into forward expectations.

Collaboration and licensing income

The defining swing factor for the current quarter, as inferred from the first-half preannouncement, is the recognition of technology licensing and collaboration revenue associated with RC148. The interim indication that operating revenue for the first half surged by approximately 433% year over year to 5.85 billion RMB, coupled with first-quarter revenue of 656.21 million RMB, implies that second-quarter revenue approximates 5.19 billion RMB—and that collaboration income accounts for the majority of this figure. Because licensing and milestone streams typically carry high margins, this revenue mix creates a substantial uplift in profitability for the quarter, consistent with the implied first-half net profit of about 4.70 billion RMB and an estimated second-quarter net profit around 4.37 billion RMB.

Investors will be looking for the disclosure granularity on milestone accounting, timelines for potential future milestones, and any guidance on royalty or profit-share economics that could recur. The reporting clarity on the proportion of upfront versus milestone components can help assess whether there is additional room for upside in subsequent quarters or whether the bulk of the step-change has already been recognized. Importantly, any commentary on the clinical and regulatory progress that conditions downstream milestone triggers will help frame the cadence of potential future cash flows.

This quarter’s collaboration income also has signaling value beyond the income statement. It underscores partner confidence in the asset and enhances funding flexibility for research and commercialization without diluting shareholders if the company chooses to temper primary issuance. Combined with previously announced share repurchase intentions, the strong non-dilutive inflow may reinforce capital allocation optionality in the coming quarters.

Quarter-specific stock drivers

The market’s near-term reaction will hinge on three elements within the quarterly disclosure. First is the scale and categorization of collaboration income relative to expectations: if the reported figure aligns with the approximate 5.19 billion RMB revenue implied for the quarter and management indicates visibility on additional milestones, investors are likely to extrapolate sustained earnings power beyond the one-off effect, supporting valuation multiples. Second is the resilience of product sales growth during a quarter dominated by collaboration income. Clear product-level commentary around telitacicept and disitamab vedotin, including hospital coverage footprint and any early signals from the new indication, will help investors assess the underlying trajectory into the second half. Third is capital management and signaling, where reinvestment plans for collaboration proceeds, potential acceleration of clinical programs, and any updates on previously publicized repurchase intentions can influence the equity story’s durability.

The quarter’s margin profile will likely reflect an outsized contribution from high-margin licensing, which should lift both gross and operating profitability above first-quarter levels. If management frames the expected normalization of margins as collaboration income moderates in future quarters while pointing to improving operating leverage in the commercial base, the stock could maintain support even as revenue mix rebalances. Finally, pipeline updates tied to RC148 and other late-stage programs can act as concurrent catalysts, reinforcing the translational value of the platform and providing a framework for medium-term milestone timing.

Analyst Opinions

The ratio of bullish to bearish opinions gathered in the period from January 1, 2026 to August 17, 2026 is 5 to 0 in favor of bullish views. Several well-known institutions maintain constructive stances: Huatai Securities reiterates a Buy rating with a target price of 143.74 Hong Kong dollars as of August 9, 2026, reflecting confidence in the earnings trajectory shaped by collaboration income and commercial execution. CICC maintains an Accumulate rating and recently raised its target price to 133.70 Hong Kong dollars on April 2, 2026, citing enhanced visibility on partnership economics and product momentum. BOCI Research holds an Outperform rating at 127.00 Hong Kong dollars (August 6, 2026), focusing on the durability of domestic sales growth and the potential for further milestone recognition. CITIC Securities keeps a Buy view as of April 14, 2026, aligning with the thesis that non-dilutive funding from out-licensing strengthens the balance between R&D investment and commercialization. Minsheng International also maintains an Outperform stance with a 125.75 Hong Kong dollars reference (July 28, 2026), emphasizing the scalability of the product portfolio and the optionality embedded in the partnership pipeline.

The bullish majority converges on three messages for the current quarter. First, the revenue and earnings run-rate implied by the half-year preannouncement sets a high bar but is viewed as achievable due to the timing and scale of the RC148 collaboration. The computed quarter-on-quarter step-up—implying around 5.19 billion RMB in revenue and roughly 4.37 billion RMB in net profit for the quarter—underpins an expectation that reported figures will substantiate the guidance’s magnitude. Second, analysts see the commercial base as a crucial validator of sustainable earnings: positive signals on telitacicept’s Sjögren’s indication and continued uptake of disitamab vedotin are expected to support an improving quality of revenue even as collaboration income normalizes over time. The expectation is that the combination of domestic sales growth and selective milestone triggers can produce a smoother earnings contour into the second half than a single-quarter spike would suggest. Third, capital deployment and pipeline acceleration are viewed as incremental positives; judicious reinvestment of collaboration proceeds to advance late-stage assets and maintain or increment shareholder returns can extend the credibility of the growth story beyond this quarter’s print.

In synthesizing the dominant view, the majority of institutions are not merely focused on the headline step-change in revenue and profit; they are assessing how the company converts this extraordinary quarter into a durable trajectory. A clean disclosure that separates collaboration income from recurring sales, combined with commentary that frames margin evolution as product mix rebalances, is seen as the most important qualitative outcome of the earnings event. Against that framework, the prevailing expectation remains that the quarter’s results will validate the half-year preannouncement, provide clarity on milestone timing, and highlight steady commercial progress—an outcome that aligns with the bullish skew in current institutional views.